Could we get to $7?
Well absolutely
That is like saying Cancer treatment does not require PS Targeting
It had always been about the IP and some will do just about anything to control it
DNA Forensics benefiting quite well from it ...as others
Interesting how Laura E Benjamin bringing in Eli Lilly employees she can trust and is it possible Peregrine had a list of partners at one point and some had to be axed due to FBI Investigations / IP patent info /research data / being sold to parties with ulterior motives etc and Eli Lilly was one of the groups they trusted...hmm, or I should say the lesser of other evils?
Interesting times ...but it will all surface
___
Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates.
Liu YW, et al. Bioconjug Chem.
2017.
Authors
Liu YW1, Shia KS1, Wu CH1, Liu KL1, Yeh YC1, Lo CF1, Chen CT1, Chen YY1, Yeh TK1, Chen WH1, Jan JJ1, Huang YC1, Huang CL1, Fang MY1, Gray BD2, Pak KY2, Hsu TA1, Huang KH1, Tsou LK1.
Author information
1
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes , Miaoli 35053, Taiwan, ROC.
2
Molecular Targeting Technologies, Inc. , West Chester, Pennsylvania 19380, United States.
Citation
Bioconjug Chem. 2017 Jul 19;28(7):1878-1892. doi: 10.1021/acs.bioconjchem.7b00225. Epub
2017 Jun 19.
Abstract
A series of zinc(II) dipicolylamine (ZnDPA)-based drug conjugates have been synthesized to probe the potential of phosphatidylserine (PS) as a new antigen for small molecule drug conjugate (SMDC) development. Using in vitro cytotoxicity and plasma stability studies, PS-binding assay, in vivo pharmacokinetic studies, and maximum tolerated dose profiles, we provided a roadmap and the key parameters required for the development of the ZnDPA based drug conjugate. In particular, conjugate 24 induced tumor regression in the COLO 205 xenograft model and exhibited a more potent antitumor effect with a 70% reduction of cytotoxic payload compared to that of the marketed irinotecan when dosed at the same regimen. In addition to the validation of PS as an effective pharmacodelivery target for SMDC, our work also provided the foundation that, if applicable, a variety of therapeutic agents could be conjugated in the same manner to treat other PS-associated diseases.
